

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV485023589U5 Express Mail Label Number October 6, 2004

Date of Deposit

Form PTO-1390-MOD (REV 10-96) U.  TRANSMITTAL LETTER TO			Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER DC/4-32448A	
			THE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	
		DESIGNATED/ELECTED O	FFICE (DO/EO/US)	10/510413	
		CONCERNING A FILING UN	NDER 35 U.S.C. 371		
INTERNATIONAL APPLICATION NO.			INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED	
PCT/EP03/04008 TITLE OF INVENTION			16 April 2003 (16.04.03)	17 April 2002 (17.04.02)	
ME PR	THO	OD FOR THE IDENTIFICATION OF IT	NHIBITORS OF THE BINDING OF A	ARE-CONTAINING MRNA AND A HUF	
		CANT(S) FOR DO/EO/US ET AL.			
App	olicar	nt herewith submits to the United States D	esignated/Elected Office (DO/EO/US) th	ne following items and other information:	
1. 2. 3.	<ul> <li>☑ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li>☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li>☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>☑ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority</li> </ul>				
5.	$\boxtimes$	date. A copy of the International Application as	s filed (35 U.S.C. 371(c)(2))		
6. 7.		<ul> <li>a.  is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b.  has been transmitted by the International Bureau. (See Form PCT/IB/308)</li> <li>c.  is not required, as the application was filed in the United States Receiving Office (RO/US).</li> <li>A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> </ul>			
8. 9. 10.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).  a.  are transmitted herewith (required only if not transmitted by the International Bureau).  b.  have been transmitted by the International Bureau.  c.  have not been made; however, the time limit for making such amendments has NOT expired.  d.  have not been made and will not be made.  A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).  An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).  A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
lter	ns 1	1. to 16. below concern document(s) or	information included.	·	
11.	$\boxtimes$	An Information Disclosure Statement und	der 37 CFR 1.97 and 1.98.	· · · · · · · · · · · · · · · · · · ·	
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13.		A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.			
14.		A substitute specification.			
15.		A change of power of attorney and/or address letter.			
16.	$\boxtimes$	Other items or information: Unexecuted Declaration and Power of Attorney; Application Data Sheet			

(b)) must be filed and granted to restore the application to pending status.

Send all correspondence to the address associated with Customer No. 001095, which is currently:

> Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080

'Q. Houghton Gregory/ Attorney for Applicants Reg. No. 47,666 (862) 778-2614